Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13333112 | 0.97 | MEN1 (0.40) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL13333122 | 0.89 | KMT2A (0.41) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL13333082 | 0.88 | MEN1 (0.41) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL13333138 | 0.88 | MEN1 (0.41) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL13332768 | 0.87 | TNF (0.41) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL13332772 | 0.87 | TNF (0.41) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL3312335 | 0.86 | MEN1 (0.41) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL13332591 | 0.86 | TNF (0.44) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL13332763 | 0.86 | MEN1 (0.41) | MEN1GAAKMT2ACNR2P2RX3 | |
| SCHEMBL13332692 | 0.86 | TNF (0.44) | MEN1GAAKMT2ACNR2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2138482-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2009-12-30 | — | — | EP | disclosed |
| EP-2138482-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | P2RY12, P2RY4, P2RY1 | MEN1 3655/4885GAA 4306/4885KMT2A 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.